Introduction
It has long been observed that subjects with Parkinson's disease (PD) have decreased olfactory sensation [1, 10, 17, 24] . Attempts to use tests of olfaction for clinical diagnosis have had mixed results, however, due to loss of olfactory ability in other conditions as well [22, 32] . Lewy bodies and synucleinopathy have been reported to be present in the olfactory bulbs of subjects with PD and dementia with Lewy bodies (DLB) as well as asymptomatic subjects with incidental Lewy body disease (ILBD) [5, 7, 9, 19, 35] , suggesting that olfactory bulb synucleinopathy is present in several Lewy body disorders and occurs at an early stage of disease. Additionally, synucleinopathy and tauopathy have been reported to co-exist in aVected olfactory bulb neurons of subjects with Alzheimer's disease [11] .
The presence of synucleinopathy in the olfactory bulb makes it theoretically possible to improve upon clinical diagnostic accuracy for Lewy body disorders during life, using olfactory bulb biopsy. However, the speciWcity and sensitivity of ollfactory bulb synucleinopathy should be established in a large autopsy series. To achieve this, we undertook immunohistochemical -synuclein staining of the olfactory bulb in 328 autopsied elderly individuals.
Materials and methods

Human subjects
The study took place at Sun Health Research Institute (SHRI), which is a non-proWt organization located in the Sun Cities retirement communities of northwest metropolitan Phoenix, AZ. Sun Health Research Institute and the Mayo Clinic Arizona are the principal members of the Arizona Parkinson's Disease Consortium. Brain necropsies and neuropathological examinations were performed on elderly subjects who had volunteered for the SHRI Brain Donation Program [3] . The Brain Donation Program has been approved by the Institutional Review Board of Sun Health Research Institute. Subjects were chosen by searching the Brain Donation Program Database for all those that died between 1 January 1997 and 31 December 2006 with clinicopathologic diagnoses of control (no clinical history of dementia or parkinsonism), PD, DLB and AD, for whom olfactory bulb tissue was available and for whom a complete set of brain blocks had been stained immunohistochemically for -synuclein. The brain regions were chosen based on published staging procedures for Parkinson's disease [6] and dementia with Lewy bodies [30] and therefore included anterior medulla, anterior pons, midbrain, amygdala, cingulate gyrus, middle temporal gyrus, middle frontal gyrus and inferior parietal lobule.
Subjects received standardized neuropathological examinations as described previously [3] . SpeciWc consensus diagnostic criteria were used for Alzheimer's disease (AD) [40], Parkinson's disease [13] and dementia with Lewy bodies [31] . For both AD and DLB, cases received the diagnosis if they were classiWed as "intermediate" or "high" probabilities in their respective classiWcation schemes. Cases with Lewy-type synucleinopathy but not meeting these diagnostic criteria were designated as either incidental Lewy body disease (ILBD) or Alzheimer's disease with Lewy-type synucleinopathy (ADLS).
All subjects were clinically characterized by review of medical records, self-report and interviews with spouses and/or caregivers. As part of the Brain Donation Program's standard protocol, 2 years of private medical records are obtained from the subjects' private physicians, both at the time of enrollment and at the time of death. A subset of subjects received standardized neuropsychological and movement disorder assessments at SHRI, including the Mini Mental State Examination (MMSE) and UniWed Parkinson's Disease Rating Scale (UPDRS).
Tissue processing and analysis ParaYn-embedded blocks of anterior medulla, anterior pons, amygdala, cingulate gyrus, middle frontal gyrus, middle temporal gyrus and inferior parietal lobule were initially stained after brain necropsy using an immunoperoxidase method for -synuclein. Sections were stained after pretreatment with proteinase K [18] using an antiserum raised against an -synuclein peptide fragment that was phosphorylated at serine 129 [12] . Color development was achieved with an avidin-biotin-horseradish peroxidase complex (ABC) and 3,3Ј-diaminobenzidine enhanced with nickel ammonium sulfate; the method has been generally described in a prior publication [4] . The same method was later used to stain paraYn-embedded olfactory bulb sections from the 328 cases, for the present study. Lewy bodies and associated neurites in the substantia nigra were identiWed in 40 m sections of midbrain stained with thioXavine S. Lewy bodies and associated neurite density were graded in all brain regions as mild, moderate, severe and very severe, according to the templates published by the Dementia with Lewy Bodies Consortium [30] .
Statistical analysis
Statistical analyses consisted of Spearman correlation of olfactory bulb synucleinopathy scores with synucleinopathy scores in other brain regions as well as with MMSE and motor UPDRS scores. Logistic regression analysis was used to obtain odds ratios as well as sensitivities and speciWcities. For the latter determinations, the dependent binary variable in all cases was diagnosis while the sole independent variable was deWned by positive or negative evidence of synucleinopathy in the olfactory bulb.
Results
Description of diagnostic groups
Of the 328 subjects with a full set of paraYn blocks available, there were 69 elderly controls, 21 ILBD, 58 PD, 35 DLB, 42 ADLS and 103 AD without synucleinopathy (ADNLS), based on prior evaluations not including examination of the olfactory bulb ( Table 1 ). The subjects ranged in age from 64 to 103, with mean ages for the diagnostic groups ranging from 79.7 (PD) to 85.7 (ILBD). Of the DLB cases, all but four also fulWlled diagnostic criteria for AD. The cases with combined DLB/AD were classiWed, for the purposes of this study, only as DLB and were not included in the AD groups.
Morpholologic characteristics of olfactory bulb synucleinopathy
In cases showing positive immunostaining for -synuclein, the stained elements usually resembled neuronal perikaryal cytoplasmic inclusions or neuritic Wbers, while a smaller fraction were dot-like, possibly representing presynaptic terminals or Wbers cut in cross-section (Fig. 1a-f ). In the great majority of cases, both perikaryal cytoplasmic inclusions and Wbers were present. Rarely, bulbs contained only perikaryal cytoplasmic inclusions or only neurites. Perikaryal inclusions were mostly in the form of round or irregular areas of cytoplasmic staining. Inclusions resembling classical Lewy bodies, with a distinguishable core-and-halo appearance, were only seen in approximately 10% of cases (Fig. 1d) . The neurites were mostly Wne and unbranching, with occasional enlarged distorted forms (Fig. 1e) that were similar to Lewyrelated neurites reported for other brain regions. The bulb region most frequently and heavily involved was the anterior olfactory nucleus, consisting of multipolar medium-sized neurons (Fig. 1a-d) , arranged in small discontinuous groups along the central axis of the bulb. The inner plexiform layer (Fig. 1f) was the next most frequently and heavily aVected area and the staining in this layer was always neuritic, without perikaryal inclusions. It is noted here that our usage of the term "anterior olfactory nucleus" is restricted to those neuronal groups that reside within the bulb itself. We did not examine the nucleus of the same name that is located near the ventral brain surface at the junction of the olfactory tract with the anterior perforated substance.
Sensitivity and speciWcity of olfactory bulb synucleinopathy for Lewy body disorders
The presence of synucleinopathy in the olfactory bulb was highly predictive of synucleinopathy elsewhere in the brain, regardless of the diagnostic classiWcation of cases. The numbers of cases, by diagnosis, found to be positive and negative, respectively, for olfactory bulb Lewy-type (Table 2) were 95% sensitive, 93% speciWc for the diagnosis of PD versus elderly control; 97% sensitive, 93% speciWc for DLB versus elderly control; 88% sensitive, 93% speciWc for ADLS versus control; 88% sensitive, 81% speciWc for ADLS versus ADNLS; 71% sensitive, 93% speciWc for ILBD versus control. The results were all statistically signiWcant (Wald P < 0.00001).
Correlation of olfactory bulb synucleinopathy score with those in other brain regions Correlation analysis (Table 3) showed that olfactory bulb synucleinopathy density scores correlated signiWcantly with those in other brain regions, with Spearman correlation coeYcients ranging from 0.46 (inferior parietal lobule) to 0.78 (amygdala). All correlations were statistically signiWcant (Spearman P < 0.0001).
Correlation of olfactory bulb synucleinopathy score with MMSE and UPDRS scores Correlation analysis (Table 3) showed that olfactory bulb synucleinopathy density scores correlated signiWcantly with MMSE and UPDRS (motor part) scores, with Spearman correlation coeYcients of ¡0.27 and 0.35, respectively.
Both correlations were statistically signiWcant (Spearman P < 0.0001).
Discussion
Olfactory bulb synucleinopathy accurately predicts the presence of Lewy body disorders
The results of this investigation show that the presence of synucleinopathy in the olfactory bulb predicts, with greater than 90% sensitivity and speciWcity, the existence of neuropathologically conWrmed PD and DLB. Additionally, olfactory bulb synucleinopathy predicts with high accuracy the presence of Lewy body pathology in subjects with AD. It is probable that olfactory bulb synucleinopathy occurs at early stages of Lewy body disorders as it is present in the majority of cases of ILBD, the suspected preclinical form of PD and/ or DLB [2] . These results also show that the severity of olfactory bulb synucleinopathy may serve as a rough guage of the severity of Lewy-related pathology throughout the CNS, as it correlates with the severity of synucleinopathy in the brainstem, limbic regions and neocortex, as well as with measures of the severity of cognitive and motor dysfunction. While it has previously been reported that the olfactory bulb is involved at early stages of Lewy body disorders [7, 19] , the sensitivity and speciWcity of olfactory bulb synucleinopathy for such conditions had not been estimated.
Olfactory bulb biopsy: possible indication for patient selection for PD surgical therapy Until now, there has not been a practical and ethical option for a biopsy diagnosis of PD. Cortical biopsy has been All brain region correlations were statistically signiWcant as were the correlations with MMSE and UPDRS (Spearman P < 0.0001 for all correlations) IX/X anterior medulla, including nuclei associated with cranial nerves IX and X; LC anterior pons, including locus ceruleus; SN midbrain, including substantia nigra; Amyg amygdala; Cing cingulate gyrus; MTG middle temporal gyrus; MFG middle frontal gyrus; PAR inferior parietal lobule performed in the past for Alzheimer's disease [16] but has generally been discontinued for ethical reasons [28] , as the harm caused by the procedure cannot be oVset by beneWts arising from accurate diagnosis. The possible usage of clinical olfactory testing as a predictive risk factor for PD has also been critiqued [26] . Pharmacologic therapy of both Alzheimer's disease and Parkinson's disease is initiated empirically as the risks of therapy are low and therapy can be discontinued if it is ineVective or causes adverse eVects. Surgical treatment of PD, however, which has included pallidotomy, thalamotomy, deep brain stimulation and neural transplantation, carries signiWcant risk of complications, up to 40% overall [15, 25, 29, 33, 34, [36] [37] [38] [39] . These therapies are thought to be ineVective for non-PD causes of Parkinsonism and therefore accurate diagnosis of PD is considered essential for patient selection. Estimates of the current clinical accuracy of the diagnosis of PD range between 65 and 90% [8, 13, 14, 20, 21, 27] , with the higher accuracy Wgures being dependent on prolonged clinical observation and therapeutic trial with levodopa. Five years of observation with a favorable response to levodopa is recommended for surgical PD candidates [25] . It has been reported that patients with multiple system atrophy (MSA) misdiagnosed as PD have undergone placement of deep brain stimulators and have not had a lasting beneWt [25] . As the characteristic glial cytoplasmic synuclein-immunoreactive inclusions of MSA are also present and diagnostic in the olfactory bulb, as reported by Kovacs et al. [23] (we have conWrmed this Wnding in Wve MSA cases), olfactory bulb biopsy would diVerentiate between PD and MSA. Olfactory bulb biopsy might therefore be useful for the evaluation of candidates for surgical therapy of PD, where the risks of biopsy might be justiWed if it would spare non-PD subjects the greater risks associated with pallidotomy, thalamotomy, deep brain stimulation or neural transplantation [15, 25, 29, 33, 34, [36] [37] [38] [39] .
Limitations of the current study
As this was an autopsy study, the entire olfactory bulb was available for examination. To achieve similar results in a biopsy setting, it is therefore recommended that the entire bulb be removed and examined. Examination of only part of the bulb may give false-negative results in some cases due to localized synucleinopathy.
Conclusions
The presence of Lewy-type -synucleinopathy in the olfactory bulb has greater than 90% sensitivity and speciWcity for neuropathologically conWrmed PD and DLB and its severity correlates with the severity of synucleinopathy in other brain regions as well as with measures of cognition and motor function. Olfactory bulb biopsy might be considered in the setting of patient evaluation for surgical therapy for PD.
